FunayamaTNozuTIshiohMIgarashiSSumiCSaitoTet al
The results of the ACHIEVE-1 study, which were presented at the ADA congress in Chicago and simultaneously published in the New England Journal of Medicine, showed that once-daily orforglipron achieved significant improvements in haemoglobin A1c a market for blood glucose control at all three doses tested compared to placebo at 40 weeks
The company's campaign acknowledges a cultural shift
This matters because much of the public buzz around these medicines is about weight loss, while many early launches may be positioned first through the diabetes route
Nshanian M, Gruber JJ, Geller BS, Chleilat F, Lancaster SM, White SM, et al
Notificaciones para declaraciones sobre estructura/funcin y declaraciones relacionadas en el etiquetado de suplementos dietticos